Clinical Trials Logo
  1. Home
  2. Locally Advanced Rectal Cancer
  3. NCT04177602

Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial

Locally Advanced Rectal Cancer Clinical Trial

Official title:
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial

Clinical Trial Summary

Seamless phase I/II trial with phase I part for determination of maximum tolerated dose (MTD) of Trifluridine/tipiracil, followed by a randomized phase II trial (randomization ratio 2:1) with an experimental arm with Trifluridine/tipiracil based chemoradiotherapy (CRT) and a standard - calibration arm (internal control) with capecitabine CRT flanked by translational research in patients with locally advanced rectal cancer

Clinical Trial Description

This is a multicenter randomized seamless phase I/II trial with a phase I for determination of maximum tolerated dose (MTD) of Trifluridine/tipiracil, followed by a randomized phase II trial (randomization ratio 2:1) with an experimental arm with Trifluridine/tipiracil in combination with standard radiotherapy and a standard - calibration arm (internal control) with capecitabine CRT flanked by translational research, designed to assess the clinical performance and efficacy of Trifluridine/tipiracil compared to current standard capecitabine chemoradiation in patients with locally advanced rectal cancer. The primary clinical objective in phase I is to determine the dosage and feasibility of Trifluridine/tipiracil based chemoradiation and in phase II whether Trifluridine/tipiracil with preoperative chemoradiation improves pathological complete remissions in patients with locally advanced rectal cancer. The secondary objectives are to evaluate Trifluridine/tipiracil chemoradiation with respect to disease free survival, overall survival, local regional failure, pathological down-staging (ypT0-2N0) rate, tumour regression grade, histopathological R0 resection rate, neoadjuvant rectal score (NAR), and perioperative complication rate. Safety and toxicity, according to NCI CTC AE v5, quality of life and feasibility of the regimen are further secondary objectives that are to be evaluated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04177602
Study type Interventional
Source Universitätsklinikum Hamburg-Eppendorf
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date November 4, 2019
Completion date September 2, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05079438 - Dendrobium Huoshanense Suppository in Rectal Cancer Phase 3
Recruiting NCT02964468 - Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer N/A
Not yet recruiting NCT05507112 - TIME in Immunotherapy Combined With nCRT for Rectal Cancer Phase 2
Not yet recruiting NCT05998122 - Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study Phase 2
Completed NCT04324567 - Inflammation After Laparoscopic Robot-assisted Surgery for Locally Advanced Rectal Cancer
Recruiting NCT05412082 - SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer Phase 1
Recruiting NCT05980689 - Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer Phase 2
Recruiting NCT02605265 - Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 Phase 3
Terminated NCT02151019 - Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer Phase 1/Phase 2
Recruiting NCT05086627 - Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer Phase 2
Not yet recruiting NCT05076305 - PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
Recruiting NCT03824899 - UGT1A1 Combined With Pharmacokinetics of SN-38 in CPT-11-based CRT in Patients With Advanced Rectal Cancer N/A
Recruiting NCT05845268 - Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer Phase 2
Completed NCT03392584 - Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters
Recruiting NCT05646511 - Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE) Phase 3
Terminated NCT02290574 - Efficacy of NeoThermo-Radio-chemotherapy for LA Rectal Cancer Before Laparoscopic TME: Prospective Phase II Trial N/A
Recruiting NCT03702985 - Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer Phase 2
Recruiting NCT05877352 - Intraoperative Electron Radiotherapy in Rectal Cancer - A Feasibility Trial N/A
Not yet recruiting NCT06375434 - Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer
Recruiting NCT04423965 - A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC Phase 2